Welcome!

News Feed Item

Stock Price Movements, Updates on Clinical Studies, Financial Results Releases, and Company Response to New Laws - Analyst Notes on Perrigo, GlaxoSmithKline, Intercept, Centene and Lorillard

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 25, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Perrigo Co. (NYSE: PRGO), GlaxoSmithKline plc (NYSE: GSK), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Centene Corp. (NYSE: CNC) and Lorillard, Inc. (NYSE: LO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1616-100free.

--
Perrigo Co. Analyst Notes
On April 22, 2014, the shares of Perrigo Co. (Perrigo) gained 4.14%, closing the day at $151.55. During the session, the Company's shares opened at $147.61 and fluctuated in the range of $147.41 - $156.00. A total of 2.19 million shares of Perrigo were traded during the day, higher than its 30-day average trading volume of 0.99 million shares. Over the previous three trading sessions, the shares of the Company increased 5.74%, as compared to the NYSE Composite, which increased 0.89% during the same period. The full analyst notes on Perrigo are available to download free of charge at:

http://www.analystsreview.com/1616-PRGO-25Apr2014.pdf

--
GlaxoSmithKline plc Analyst Notes
On April 22, 2014, GlaxoSmithKline plc (GSK) and Theravance, Inc. (Theravance) jointly announced the beginning of a Phase III efficacy and safety study of a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate and long-acting beta2 agonist (LABA), vilanterol (FF/VI). The study will be conducted to evaluate the contribution of the ICS component on lung function, in patients with Chronic Obstructive Pulmonary Disease (COPD). The Company informed that the positive results from this study will help support a potential filing of FF/VI for the treatment of patients with COPD in Japan. According to GSK, the study involves a 12 week, multicentre, randomised, double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25mcg once daily compared with VI 25mcg once daily, administered through the Ellipta inhaler. The full analyst notes on GlaxoSmithKline are available to download free of charge at:

http://www.analystsreview.com/1616-GSK-25Apr2014.pdf

--
Intercept Pharmaceuticals, Inc. Analyst Notes
On April 12, 2014, Intercept Pharmaceuticals, Inc. (Intercept) announced the results from the Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) to be presented in a late-breaker session at the International Liver Congress of the European Association for the Study of the Liver (EASL). Mark Pruzanski, M.D., CEO of Intercept, commented, "We believe OCA can fill a major gap in the treatment of PBC by providing an effective second-line therapy for the up to 50% of patients who do not achieve an adequate response with ursodiol, the current standard of care." Intercept plans to submit data from the Phase 3 POISE trial and the two Phase 2 trials of OCA for the treatment of PBC as part of a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency. The full analyst notes on Intercept are available to download free of charge at:

http://www.analystsreview.com/1616-ICPT-25Apr2014.pdf

--
Centene Corp. Analyst Notes
On April 22, 2014, Centene Corp. (Centene) announced its financial results for Q1 2014. The Company reported a 37.0% increase in revenues to $3.5 million, driven mainly by its expansions in Florida and Ohio, the additions of the California, New Hampshire and three Centurion contracts, the Company's participation in the Health Insurance Marketplaces, and the acquisitions of AcariaHealth and U.S. Medical Management. Net earnings for the quarter came in at $33.0 million, or $0.56 per diluted share, as compared to $23.0 million, or $0.42 per diluted share, in Q1 2013. Centene's adjusted diluted EPS of $0.79 was significantly higher than $0.46 as forecasted by analysts, on average, polled by Bloomberg. Looking ahead, the Company expects the full year 2014 diluted EPS to be in the range of $3.60 - $3.90. Centene's stock rallied 12.22% to close at $64.29 following the announcement. The full analyst notes on Centene are available to download free of charge at:

http://www.analystsreview.com/1616-CNC-25Apr2014.pdf

--
Lorillard, Inc. Analyst Notes
On April 14, 2014, Lorillard, Inc. (Lorillard) issued a press release to appreciate the legislation signed into law by Kentucky Gov. Steve Beshear, which will bar minors from buying electronic cigarettes. Murray S. Kessler, Chairman, President and CEO of Lorillard, said: "The Kentucky law demonstrates that it is possible to find common ground and sell responsibly to adults. It would be a mistake to let old divisions affect the development of electronic cigarettes, a new product with the potential to play a critical role in the national harm reduction discussion. Lorillard has actively supported age of purchase legislation in the states and encourages states that have not passed similar legislation to do so." The Company believes that it is also necessary to pass state laws prohibiting the sale of e-cigarettes to minors as many state do not disallow selling, furnishing and distributing electronic cigarettes to minors. The full analyst notes on Lorillard are available to download free of charge at:

http://www.analystsreview.com/1616-LO-25Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


AnalystsReview.com

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
UpGuard has become a member of the Center for Internet Security (CIS), and will continue to help businesses expand visibility into their cyber risk by providing hardening benchmarks to all customers. By incorporating these benchmarks, UpGuard's CSTAR solution builds on its lead in providing the most complete assessment of both internal and external cyber risk. CIS benchmarks are a widely accepted set of hardening guidelines that have been publicly available for years. Numerous solutions exist t...
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
The competitive landscape of the global cloud computing market in the healthcare industry is crowded due to the presence of a large number of players. The large number of participants has led to the fragmented nature of the market. Some of the major players operating in the global cloud computing market in the healthcare industry are Cisco Systems Inc., Carestream Health Inc., Carecloud Corp., AGFA Healthcare, IBM Corp., Cleardata Networks, Merge Healthcare Inc., Microsoft Corp., Intel Corp., an...
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
StackIQ has announced the release of Stacki 3.2. Stacki is an easy-to-use Linux server provisioning tool. Stacki 3.2 delivers new capabilities that simplify the automation and integration of site-specific requirements. StackIQ is the commercial entity behind this open source bare metal provisioning tool. Since the release of Stacki in June of 2015, the Stacki core team has been focused on making the Community Edition meet the needs of members of the community, adding features and value, while ...
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...